Venture Capital

Kerna Ventures

Investment Details

Investor Type
Venture Capital

Asset Class Focus
Private Equity, Venture Capital

Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO, Buyout, Turnaround, Distressed

Geographical Focus
United States, United Kingdom, Germany, France, Italy, Denmark, Switzerland, Spain, Ireland, Austria, Netherlands, Hungary, Portugal, Sweden, Belgium, Greece, Norway, Finland, Poland, Czech Republic

Industries Focus

  • Healthcare
  • Artificial Intelligence
  • Digital Health
  • Pharmaceuticals
  • Medical Devices
  • Diagnostics
  • Machine Learning
  • Biotechnology
  • Oncology
  • Neurology
  • Cardiology
  • Endocrinology
  • Immunology
  • Genomics
  • Orthopedics

Investment Size:
500,000 to 5,000,000 USD

Investor Details Founded: 2022

Kerna Ventures is a London-based venture capital firm established in 2022. The firm specializes in early-stage investments in advanced therapeutic platform technologies, focusing on areas such as genome engineering, cell reprogramming, and computational biology. Kerna Ventures primarily invests in seed through Series A stages, with ticket sizes ranging from $500,000 to $5 million. The firm's portfolio includes companies like GenEdit, Axent, Nodal Therapeutics, Renewal Bio, Geneditor, Pasqal, and Proteinea. Kerna Ventures is committed to supporting innovative startups that aim to revolutionize healthcare through cutting-edge scientific advancements.

Requirements
  • Innovative technology startups
  • Advanced therapeutic platform technologies
  • Seed through Series A stages
  • Ticket sizes between $500,000 and $5 million
Contact

[Official Website Hidden]

[LinkedIn Profile Hidden]

[HQ Location Hidden]

[Email Hidden]

Portfolio Companies
  • GenEdit
  • Axent
  • Nodal Therapeutics
  • Renewal Bio
  • Geneditor
  • PASQAL
  • Proteinea
Claim this Investor

Are you an official representative of Kerna Ventures?

Claim this investor to update information, manage your profile, and get a verified seal.

Claim